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Abstract Lipoxygenases form a family of lipid peroxidising
enzymes, which oxygenate free and esterified polyenoic fatty
acids to the corresponding hydroperoxy derivatives. They are
widely distributed in both the plant and animal kingdoms. During
the last couple of years more and more lipoxygenase isoforms
have been discovered but for most of them the biological
significance remains unclear. This review attempts to classify
the currently known mammalian lipoxygenase isoforms and
critically reviews the concepts for their biological importance.
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1. Introduction
Lipoxygenases (LOXs) form a family of lipid peroxidising
enzymes, which occur in both the plant and animal kingdoms
[1]. LOXs have also been detected in lower marine organisms
(sea urchins, star¢sh, surf clams and corals [2^5]), but they are
obviously not expressed in bacteria or yeast. Most of our
early knowledge on LOXs originates from studies of the soy-
bean LOX-1 and other plant isoenzymes. However, because of
space limitations the present review will focus on mammalian
LOXs only.
For a long time it was believed that LOXs did not occur in
animals but in 1974 the formation of (12S,5Z,8Z,10E,14Z)-
12-hydroxyeicosa-5,8,10,14-tetraenoic acid (12-HETE) was
described, when human thrombocytes were incubated with
exogenous arachidonic acid [6]. This discovery marked the
starting point of animal LOX research and over the following
years more and more LOX isoforms were discovered. In 1975
a LOX was detected in rabbit reticulocytes, which was capable
of oxidising phospholipids and biomembranes [7]. This en-
zyme was puri¢ed to homogeneity and well characterised
with respect to its protein chemical and enzymatic properties
[8]. For the time being it is the only animal LOX for which the
three-dimensional X-ray structure is available [9]. The struc-
tural identi¢cation of the slow reacting substance of anaphy-
laxis [10] and the ¢nding that arachidonate 5-LOXs are in-
volved in leukotriene biosynthesis marked a milestone in
animal LOX research and prompted many scientists to inten-
sify their activities in this ¢eld.
Starting in 1974 the diversity of the mammalian LOX fam-
ily has been growing constantly. Meanwhile 18 di¡erent LOX
sequences have been published representing at least seven dif-
ferent isoforms analysed in seven mammalian species. Among
the di¡erent species the diversity of the LOX family is best
investigated in mice. Six di¡erent LOX isoforms encoded by
six di¡erent genes have been described so far in mice and it
may be predicted that in the near future the diversity of the
LOX family is expected to grow further. There are unpub-
lished data in our laboratories, and in other laboratories sug-
gesting that the expression pattern of LOXs in mice and other
mammals may be even more complex.
In sharp contrast to the multiplicity of sequence informa-
tion there are few clear cut data as to the biological relevance
of these enzymes. The role of 5-LOX in the biosynthesis of
leukotrienes is generally accepted [11]. The reticulocyte-type
15-LOXs have been implicated in cell maturation and di¡er-
entiation [12,13] and several lines of experimental evidence
support this hypothesis. However, the ¢nal proof is still lack-
ing. Unfortunately, for all other LOX isoforms our knowledge
of their biological roles is very limited.
This review is intended to stress the discrepancy between
the growing knowledge of the structural biology of mamma-
lian LOXs on the one hand and the disappointing advance-
ment in the ¢eld of the biological importance of these en-
zymes. In this respect the current situation in LOX research
mirrors the situation of the human genome project. Plenty of
structural data are already available but their functional rele-
vance remains to be investigated in the future.
2. Stereochemistry of the LOX reaction
Although the detailed mechanism of the LOX reaction still
remains a matter of discussion its radical nature is commonly
agreed upon. Formally, the LOX reaction consists of three
consecutive steps (Fig. 1): (i) stereo-selective hydrogen ab-
straction from a doubly allelic methylene group; (ii) radical
rearrangement ([+2] and [32] [14]) which is accompanied by a
Z,E-diene conjugation; (iii) stereospeci¢c (S- or R-) insertion
of molecular dioxygen and reduction hydroperoxy radical in-
termediate to the corresponding anion. From the stereochem-
ical point of view each of these steps can proceed in di¡erent
ways.
2.1. Hydrogen abstraction
With arachidonic acid as substrate hydrogen can be re-
moved from three di¡erent doubly allelic methylenes (C-7,
C-10, C-13). Since each double allelic methylene binds a
pro-S and a pro-R hydrogen, six di¡erent hydrogen atoms
FEBS 21864 12-4-99
0014-5793/99/$20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 3 9 6 - 8
*Corresponding author. Fax: (49) (30) 2093 7300.
E-mail: hartmut.kuehn@rz.hu-berlin.de
1 This paper is dedicated to Prof. Shozo Yamamoto to honor his
achievements in lipoxygenase research.
FEBS 21864 FEBS Letters 449 (1999) 7^11
may be removed. However, most mammalian LOXs select just
one hydrogen and which one depends on the orientation of
the substrate fatty acid at the active site.
2.2. Radical rearrangements
The classical mechanism of the LOX reaction involves the
formation of a pentadienyl radical. In this intermediate the
density of the radical unpaired electron may be delocalised
over the entire pentadienyl system which requires a planar
structure of this part of the substrate molecule (Fig. 1). How-
ever, more recent structural data [15] suggest that the forma-
tion of a planar pentadienyl radical may be hindered steri-
cally. Thus, the formation of a dioxygen-bridged allyl
radical was proposed in which the radical electron may not
be delocalised over the entire pentadienyl system but rather
over a part of it. Recent spectroscopic studies on the interac-
tion of the soybean LOX-1 with linoleic acid suggested the
formation of such a dioxygen bridged allyl radical [16]. Ac-
cording to this hypothesis the direction of the radical rear-
rangement ([+2] or [32]) depends on the conformation the
fatty acid may adapt at the active site.
2.3. Oxygen insertion
At the present time it is believed that LOXs may have
neither a speci¢c dioxygen binding site nor a separate tunnel
through which the second substrate may penetrate into the
active site. Instead, it has been suggested that oxygen insertion
proceeds di¡usion-controlled and that the gas may pass
through the fatty acid binding cavity. If this is true additional
assumptions must be made in order to explain the high degree
of chirality of most LOX products.
3. Diversity of the lipoxygenase family and lipoxygenase c
lassi¢cation
According to the currently used nomenclature, LOXs are
categorised with respect to their positional speci¢city of arach-
idonic acid oxygenation. Until recently it was believed that
three major LOX isoforms may exist in mammals: (i) arach-
idonate 5-LOXs which introduce molecular dioxygen at car-
bon 5 of the arachidonic acid backbone, (ii) arachidonate 12-
LOXs which catalysed the formation of (12S,5Z,8Z,10E,14Z)-
12-hydroperoxyeicosa-5,8,10,14-tetraenoic acid (12S-HpETE)
FEBS 21864 12-4-99
Fig. 1. Radical mechanism of the lipoxygenase reaction.
Fig. 2. Phylogenetic tree of mammalian LOXs.
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and (iii) arachidonate 15-LOXs which oxygenate the substrate
fatty acid at C-15. The arachidonic acid based nomenclature
is straightforward and commonly accepted by the scienti¢c
community. However, the growing diversity of the LOX fam-
ily requires a modi¢cation of this nomenclature since the old
one groups together LOX isoforms, which are phylogeneti-
cally not closely related and clearly di¡er from each other
with respect to their enzymatic properties (e.g. human retic-
ulocyte-type 15S-LOX vs human epidermis-type 15S-LOX).
On the other hand, according to the old nomenclature the
rabbit leukocyte-type 12-LOX and the rabbit reticulocyte-
type 15-LOX are categorised into di¡erent groups (12-LOX
vs 15-LOX) despite the fact that they are 99% identical at the
amino acid level. Similarly, the mouse leukocyte-type 12-LOX
is more closely related to the human reticulocyte-type 15-LOX
than to the mouse platelet-type 12-LOX and thus, the ¢rst
two enzymes should be grouped together instead of the latter
two.
Looking at the phylogenetic tree of mammalian LOXs (Fig.
2) it becomes evident that these enzymes may be sub-divided
into four groups [17^34]. All leukocyte-type 12-LOXs and the
reticulocyte-type 15-LOXs may be grouped together. This
classi¢cation also makes sense from the enzymological point
of view since these LOX isoforms are very similar to each
other with respect to their enzymatic properties (substrate
speci¢city, reactivity with complex lipid-protein assemblies
[35]). Chimeric LOXs constructed from these isoforms are
enzymatically active [36] and the positional speci¢city of
arachidonic acid oxygenation is altered if critical amino acids
are interchanged [36,37]. In contrast, attempts to construct
chimera between platelet-type 12-LOXs and reticulocyte-type
15-LOXs did not lead to active LOX species (unpublished
data). Currently it is not clear whether the mouse epidermal
12(S)-LOX should be included in this group. Although the
sequence data support such a classi¢cation, the enzyme may
di¡er from other members of this family with respect to its
enzymatic properties. However, more detailed functional
characterisation of this enzyme is needed to decide its ¢nal
assignment.
The more recently discovered epidermis-type LOXs [31^34]
may be grouped together although their positional speci¢city
of arachidonic acid oxygenation is rather heterogeneous. Since
the positional speci¢city of LOXs may re£ect the spatial ori-
entation of the substrate fatty acid at the active site, the struc-
tural features within the substrate binding pockets of these
isoenzymes must be di¡erent. On the other hand, the human
epidermis-type 15(S)-LOX shares a high degree (78%) of over-
all amino acid similarity (Fig. 3) with the mouse epidermis-
type 8-LOX and in the region of the putative substrate bind-
ing cleft the similarity is even higher. However, when the
reaction characteristics of both isoforms are compared one
may conclude that the steps of the LOX reaction have a
di¡erent stereochemistry (C-13 vs C-10 hydrogen removal,
[+2]- vs [32]-radical rearrangement). Unfortunately, for the
time being, there are no direct structural data available for
any of the epidermis-type LOXs and structural models on the
basis of the X-ray data of the rabbit reticulocyte 15-LOX may
not be useful because of the low degree of amino acid homol-
ogy.
4. Biological role of mammalian lipoxygenases
For most LOX isoforms their biological roles are far from
being clear. According to the concept of the arachidonic acid
cascade LOXs are involved in the biosynthesis of lipid hor-
mones such as leukotrienes, lipoxins and/or hydroxy fatty
acids. However, certain LOX subtypes (reticulocyte-type
15(S)-LOXs, leukocyte-type 12(S)-LOXs) may play a biolog-
ical role outside the arachidonic acid cascade.
5-LOXs are involved in the biosynthesis of leukotrienes,
which constitute mediators of anaphylactic and in£ammatory
disorders [11]. Leukotriene antagonists and leukotriene syn-
thesis inhibitors are currently being tested in clinical trials for
their anti-asthmatic and/or anti-in£ammatory potencies and
preliminary results are very promising. Under certain condi-
tions the 5-LOX is also expressed in cells which may not be
related to anaphylactic and/or in£ammatory reactions [38].
Thus, there may be additional roles for this enzyme outside
the arachidonic acid cascade. Moreover, the intranuclear lo-
calisation of the 5-LOX in resting human alveolar macro-
phages [39] may suggest that the 5-LOX and/or 5-LOX prod-
ucts might be important for the regulation of gene expression.
The reticulocyte-type 15-LOX has been implicated in cell
development and di¡erentiation. During the maturation of
rabbit reticulocytes this enzyme initiates the cytosolic break-
down of the remaining mitochondria during reticulocyte/
erythrocyte transition [12]. Human peripheral monocytes do
not express this type of 15-LOX [40] but in macrophages,
which develop from peripheral monocytes, enzyme expression
can be detected [41]. These data suggest a biological role of
the enzyme either in monocyte/macrophage transitions and/or
in macrophage function. Recently, it was reported that an
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Fig. 3. Mutiple amino acid sequence comparison between mammalian LOXs.
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arachidonic acid 15-LOXs might be involved in organelle deg-
radation during di¡erentiation of the eye lens cell [13]. During
the past couple of years an implication of 12/15-LOXs in
atherogenesis has been discussed [42,43]. The enzyme is ex-
pressed in foamy macrophages [44] and is capable of oxidising
low density lipoprotein in vitro to an atherogenic form [45].
Speci¢c 12/15-LOX products can be detected in young athe-
rosclerotic lesions [46] indicating the enzymes functionality.
However, there is currently a debate in the literature about
whether the LOX may act pro- and/or anti-atherogenically
[47,48].
The possible role of 12/15-LOXs in cell di¡erentiation and
atherogenesis is related to its capability of oxygenating poly-
enoic fatty acids esteri¢ed to complex lipid/protein assemblies
(biomembranes, lipoproteins). On the other hand, it may well
be that these LOXs may also exhibit biological activities via
the formation of bioactive lipids. In fact, the major products
of 12/15-LOX pathway namely (12S,5Z,8Z,10E,14Z)-12-hy-
dro(pero)xyeicosa-5,8,10,14-tetraenoic acid [12S-H(p)ETE),
(15S,5Z,8Z,11Z,13E)-15-hydro(pero)xyeicosa-5,8,11,13-tetra-
enoic acid [15S-H(p)ETE] and (13S,9Z,11E)-13-hydro(pero)xy-
octadeca-9,11-dienoic acid [13-H(p)ODE], are bioactive in cel-
lular and supracellular assay systems [49]. However, it remains
to be investigated whether these e¡ects may be of physiolog-
ical relevance in vivo.
For the other LOX isoforms, particularly for the platelet-
type 12-LOXs and for the epidermis-type LOXs little is
known about their biological role. 12-LOXs of either type
have been implicated in the biosynthesis of hepoxilins and
lipoxins. Hepoxilins may be involved in the regulation of
ion transport across biomembranes and thus, 12-LOXs may
play a role. Lipoxins which can be synthesised unicellularly in
leukocytes via a concerted action of 5- and 12/15-LOXs or
transcellularly by the leukocyte 5-LOX and the platelet 12-
LOX appear to be involved in the regulation of immunolog-
ical and haemodynamic processes. Here again, it remains to
be shown whether any of these e¡ects may be of biological
importance in vivo.
5. Perspective
The discrepancy between the rapidly increasing knowledge
of the structural biology of LOXs and the disappointing ad-
vances in research of the biological role of these enzymes may
re£ect a general trend in biomedical research. As a conse-
quence of the human genome project tools and techniques
for structural molecular biological research have been rapidly
developed during the past several years. These days it may not
be a major problem any longer to identify new LOX sequen-
ces using PCR techniques with degenerated primer combina-
tions and commercially available DNA libraries. Primers can
be easily designed by sequence comparison of database entries
using programs which can be downloaded from the Internet.
In contrast, in order to investigate the biological role of any
enzyme more complex studies are required. Speci¢c LOX in-
hibitors and/or transgenic animals (LOX knock outs or LOX
overexpressing animals) are important tools for these kinds of
investigations. Unfortunately only a few more or less speci¢c
LOX inhibitors are available, and two strains of LOX knock
out mice have been established to date. Although both inhib-
itor studies and experiments with transgenic animals have
gaps (e.g. lacking overall speci¢city, redundancy of LOX fam-
ily) a combination of such experiments may be successful.
Hopefully, more and more strains of LOX knock out mice
and more speci¢c LOX inhibitors may become available in the
near future. With these tools in our hands we might be able to
close the gap between structural and functional LOXs re-
search.
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